InflaRx IFRX
NASDAQ IFRX
$1.53 -0.02 (-1.29%)
At close: Oct 22, 2026 · 4:00 PM EDT

InflaRx (IFRX) Price to Sales (2024 - 2026)

Updated

InflaRx's (IFRX) Price to Sales stood at 2054.21 in Q2 2026, up 855.4% from 215.01 a year earlier.

Analysis

InflaRx (IFRX) Price to Sales (2024 - 2026) Analysis & Trends

For FY2025, InflaRx's Price to Sales came in at 2203.35, up 166.3% from FY2024.

  • Across earlier years, Price to Sales came in at 827.49 in FY2024 (-41.5%) and 1413.96 in FY2023.
  • The Q2 2026 figure is the highest quarterly Price to Sales in data going back to Q2 2024.
  • On a year-over-year basis, Price to Sales rose in three of the last four quarters, with growth averaging 213.8%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 InflaRx 110.61 Mn -223.01 Mn 2.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2,054.21
Dec 31, 2025 1,029.79
Sep 30, 2025 723.35
Jun 30, 2025 215.01
Mar 31, 2025 335.80
Dec 31, 2024 807.60
Sep 30, 2024 488.47
Jun 30, 2024 893.69
Mar 31, 2024 844.78
API Access

InflaRx Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=IFRX&period=max&api_key=YOUR_API_KEY